Search results
Geron surges after winning first US FDA approval for blood disorder drug
Reuters via Yahoo News· 11 hours agoFood and Drug Administration for its blood disorder drug. The health regulator's nod allows the ...
Geron stock steady as analysts maintain 'buy' rating with $10 target By Investing.com
Investing.com· 3 hours agos drug Rytelo (imetelstat) received approval for the treatment of adults with transfusion-dependent...
Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers
Investopedia· 14 hours agoGeron (GERN) shares skyrocketed over 19% in intraday trading Friday after the Food and Drug ...
Geron Shares Surge After U.S. FDA Approves Blood Disorder Drug
US News & World Report· 11 hours agoThe injectable drug will compete with Bristol Myers Squibb's Reblozyl, which received a label expansion green light by the regulator last year for the same ...
I-Mab and Bristol Myers team up for cancer drug trial By Investing.com
Investing.com· 2 days agoSquibb (NYSE: NYSE:BMY) to conduct a clinical trial for advanced gastric and esophageal cancer...
Very good news for Geron stock price: now what? | Invezz
Invezz· 10 hours agoGeron Corporation (NASDAQ: GERN) stock price went vertical on Friday as investors cheered the latest...
Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO
BioPharma Dive via Yahoo Finance· 10 hours agoAfter 34 years, Geron finally has an approved medicine in Rytelo. Elsewhere, Shionogi disclosed...
Geron Corp stock opened 25% up on Friday: here's why | Invezz
Invezz· 7 hours agoAre you looking for signals & alerts from pro-traders? The Food & Drug Administration approved its lead asset as a late-line treatment ...
2 No-Brainer Dividend Stocks You Can Buy With $100 in June
Motley Fool via Yahoo Finance· 4 days agoThe company's growth portfolio raised first-quarter sales by 11% year over year if we exclude the...
Bristol’s $250,000 pill slows lung cancer growth by 7 weeks
San Francisco Chronicle· 4 days agoA Bristol Myers Squibb Co. lung cancer treatment delayed tumor growth by less than seven weeks in a closely watched clinical trial, a disappointing result after the company ...